TOKIWA-Bio Inc.
PrivateLast Round
Series B
Oct 20, 2025
Total Funding Raised
$5.47M
Company Overview
TOKIWA-Bio Inc. is a biotechnology company that develops and commercializes its Stealth RNA Vector (SRV) technology for gene therapy, regenerative medicine, and biopharmaceutical manufacturing.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
TOKIWA-Bio Inc. Comparables
Compare TOKIWA-Bio Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| ReproCELL Incorporated | 78% | |
| I'rom Group Co., Ltd. | 76% | |
| Eli Lilly and Company | 72% |
TOKIWA-Bio Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Oct 20, 2025 | ||||
| Series A | Nov 10, 2017 |
TOKIWA-Bio Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Tohoku University Venture Partners | Series B |
| 日本ベンチャーキャピタル株式会社 | Series A |
| Kyoto University Innovation Capital | Series B |
| Japan Science and Technology Agency | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 12, 2025
Monthly visitors grew 76% MoM, reaching 2.3K.
- May 2, 2025
Monthly visitors increased 281% MoM.
Recent news
Latest coverage and updates
- attends_eventOct 9, 2026
TOKIWA-Bio, Inc. holds a joint signing ceremony for a strategic partnership at BioJapan 2026 in Japan on Oct 9th '26
- is_developingJul 20, 2026
Tokiwa-Bio Inc. is developing method for generating red blood cell-like cells on Jul 20th '26.
TOKIWA-Bio Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about TOKIWA-Bio Inc.'s valuation, stock price, and market status.
Is TOKIWA-Bio Inc. a public or private company?
TOKIWA-Bio Inc. is a private company.
What is the current stock price of TOKIWA-Bio Inc.?
TOKIWA-Bio Inc. is a private company, so its shares have no public market price. Caplight tracks TOKIWA-Bio Inc.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is TOKIWA-Bio Inc. worth (valuation)?
Valuation information for TOKIWA-Bio Inc. is not publicly available.
Can I buy TOKIWA-Bio Inc. stock?
TOKIWA-Bio Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was TOKIWA-Bio Inc.'s last funding round?
TOKIWA-Bio Inc.'s most recent funding round was Series B on October 20, 2025.
Who are the main investors in TOKIWA-Bio Inc.?
Key investors in TOKIWA-Bio Inc. include Tohoku University Venture Partners, Kyoto University Innovation Capital.
Will TOKIWA-Bio Inc. IPO soon?
No public IPO plans have been announced for TOKIWA-Bio Inc..
How can I track TOKIWA-Bio Inc. secondary market activity?
Caplight tracks bids, offers, and trades in TOKIWA-Bio Inc.'s shares on secondary markets.